### THIS WEEK IN Neurology®

871 Highlights of the September 16 issue

### EDITORIALS

872 From clues to mechanisms: Understanding ALS initiation and spread
*Carmel Armon*

874 Advancing age, impending death, and declining cognition
*Robert S. Wilson*

### ARTICLES

876 Natural history of young-adult amyotrophic lateral sclerosis
*M. Sabatelli, F. Madia, A. Conte, M. Luigetti, M. Zollino, I. Mancuso, M. Lo Monaco, G. Lippi, P. Tonali*

882 Onset of terminal decline in cognitive abilities in individuals without dementia

888 Detecting navigational deficits in cognitive aging and Alzheimer disease using virtual reality
*L.A. Cushman, K. Stein, and C.J. Duffy*

896 PINK1 mutations and parkinsonism

903 Imaging amyloid deposition in Lewy body diseases

911 T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome
*L.G. Astrakas, S. Konitsiotis, P. Margariti, S. Tsouli, L. Tzarouhi, and M.I. Argyropoulou*

917 CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial

925 Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids

930 Neuronal surface antigen antibodies in limbic encephalitis: Clinical-immunologic associations
*F. Graus, A. Saiz, M. Lai, J. Bruna, F. López, L. Sabater, Y. Blanco, M.J. Rey, T. Ribalta, and J. Dalmau*

937 Burden of atherosclerosis and risk of venous thromboembolism in patients with migraine
*J. Schwaiger, S. Kiechl, H. Stockner, M. Knoflach, P. Werner, G. Rungger, A. Gasperi, and J. Willeit*

### CLINICAL IMPLICATIONS OF NEUROSCIENCE RESEARCH

944 The midline and intralaminar thalamic nuclei: Anatomic and functional specificity and implications in neurologic disease
*Eduardo E. Benarroch*

### CLINICAL/SCIENTIFIC NOTES

950 Double-blind, placebo-controlled, pilot trial of botulinum toxin A in restless legs syndrome
*F.B. Nahab, E.L. Peckham, and M. Hallett*
Fine-mapping the gene for X-linked myopathy with excessive autophagy

Brainstem compression by “kissing vertebral arteries”

REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia
To the Editor: David Benninger, Daniel Waldvogel, and Claudio L. Bassetti. Reply from the Authors: J.-F. Gagnon, M. Vendette, R.B. Postuma, and J. Montplaisir

Dyslipidemia is a protective factor in amyotrophic lateral sclerosis
To the Editor: Mark R. Goldstein, Luca Mascitelli, and Francesca Pezzetta. Reply from the Authors: Vincent Meininger, Luc Dupuis, and Jean-Philippe Loeffler

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

Imaging amyloid deposition in Lewy body diseases
The weekly podcast of content from Neurology is located on the AAN Web site at www.aan.com. Select the “podcast” button in the Neurology section under Publications Highlights to subscribe to the podcasts or listen to an individual podcast.

This week’s podcast features an interview by Dr. Jeff Burns with Dr. Stephen Gomperts about his paper on imaging amyloid deposition.

Earn CME while reading Neurology. This program is available only to online Neurology subscribers. Simply read the articles marked CME, go to www.neurology.org, and click on CME. This will provide all of the information necessary to get started. The American Academy of Neurology (AAN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Neurology is planned and produced in accordance with the ACCME Essentials. For more information, contact AAN Member Services at 800-879-1960.